Full-Time

Engineering Technician

Night Shifts

Confirmed live in the last 24 hours

AstraZeneca

AstraZeneca

10,001+ employees

Develops and commercializes prescription medicines

No salary listed

Entry, Junior

Buxton, UK

This position requires in-person working five days per week from the office.

Category
Manufacturing Engineering
Mechanical Engineering
Requirements
  • Recognised Engineering Apprenticeship or equivalent
  • ONC/HNC or equivalent in a relevant engineering field
  • Experience in Electrical, Mechanical and Instrumentation subject areas (Maintenance and Fault Finding)
Responsibilities
  • Provide swift breakdown support for various pharmaceutical assets and processes within the aseptic manufacture facilities.
  • Investigate and identify root causes using structured problem-solving methodologies.
  • Actively lead and deliver continuous improvement activities and projects using lean and manufacturing methodologies such as RCM, TPM and CBM.
  • Work closely with production operators to provide equipment training and coaching.
Desired Qualifications
  • Experience working with automated machinery
  • Experience of working compliantly to GMP & SHE procedures.
  • Familiar with CMMS (SAP PM)
  • Knowledge of IT systems e.g. Drawing/Document Management Systems, Microsoft office, Building Management Systems, PCs, PLCs
  • Knowledge of TPM, Root Cause Analysis and Continuous Improvement
  • Knowledge of Project / Change management

AstraZeneca focuses on discovering, developing, and selling prescription medicines. The company specializes in three main areas: Oncology, which deals with cancer treatments; Cardiovascular, Renal & Metabolism, which addresses heart, kidney, and metabolic diseases; and Respiratory & Immunology, which targets lung and immune system diseases. Their products are developed through extensive research and development, followed by clinical trials and regulatory approvals before they reach the market. AstraZeneca differentiates itself from competitors by investing heavily in scientific research and forming strategic partnerships to enhance drug discovery. Their goal is to advance healthcare by creating effective treatments for serious diseases and collaborating with other organizations to improve their research capabilities.

Company Size

10,001+

Company Stage

IPO

Headquarters

Cambridge, United Kingdom

Founded

1913

Simplify Jobs

Simplify's Take

What believers are saying

  • AI-driven drug discovery enhances AstraZeneca's R&D efficiency and innovation.
  • Real-world evidence supports AstraZeneca's drug efficacy and safety demonstrations.
  • Personalized medicine aligns with AstraZeneca's focus on precision oncology treatments.

What critics are saying

  • Class-action lawsuit over Soliris could lead to financial penalties and reputational damage.
  • AI tool for breast cancer screening may face challenges due to minority underrepresentation.
  • Investment in Dunkirk production lines may be affected by changes in French regulations.

What makes AstraZeneca unique

  • AstraZeneca excels in oncology, cardiovascular, and respiratory therapeutic areas.
  • The A.Catalyst Network fosters global collaboration and innovation in healthcare.
  • Open Innovation program accelerates drug discovery by sharing resources with the scientific community.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

401(k) Retirement Plan

Paid Vacation

Paid Holidays

Flexible Work Hours

Company News

Life Sciences IP Review
Apr 17th, 2025
AstraZeneca unit faces class-action suit over alleged Soliris monopoly

AstraZeneca unit faces class-action suit over alleged soliris monopoly.

Our Health Needs
Apr 11th, 2025
Study: Racial, ethnic minorities are underrepresented in AI mammogram interpretation

In 2024, AI biotech company Owkin partnered with pharma giant AstraZeneca to develop an AI-powered tool designed to pre-screen for gBRCA mutations (gBRCAm) in breast cancer directly from digitized pathology slides.

Medical Update Online
Apr 11th, 2025
AstraZeneca showcases progress in immunisation and real-world evidence addressing global infectious disease burden at ESCMID Global 2025

AstraZeneca showcases progress in immunisation and real-world evidence addressing global infectious disease burden at ESCMID Global 2025.

Cision
Apr 11th, 2025
Result Of Agm

11 April 2025Results of Annual General Meeting held on 11 April 2025AstraZeneca PLC announced the results of the voting at its Annual General Meeting (AGM) today. As proposed in the Notice of AGM, all Resolutions were decided by poll vote. Resolutions 9 - 12 were passed as special resolutions; all other resolutions were passed as ordinary resolutions.Resolution. Votes for. % of votes cast

Europawire
Apr 8th, 2025
AstraZeneca Unveils Breakthrough Data on Vaccines and Antibody Therapies for Infections

AstraZeneca unveils breakthrough data on vaccines and antibody therapies for infections.